Benefits and safety of landiolol for rapid rate control in patients with atrial tachyarrhythmias and acute decompensated heart failure

Tsuyoshi Shiga*

Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, Tokyo, Japan

KEYWORDS
Atrial fibrillation; Beta blockers; Landiolol; Heart failure; Rate control

Atrial tachyarrhythmias often occur in patients with worsening heart failure (HF), and the development of atrial tachyarrhythmias in acute decompensated HF (ADHF) causes an uncontrolled heart rate (HR) and leads to further exacerbation of HF and persistence of a decompensated HF state. Landiolol, a short-acting intravenous beta-1 blocker, shows very high cardiac beta-1 selectivity and has a very short elimination half-life of approximately 4 min. As shown in several reports, the benefit of intravenous landiolol is that it lowers the ventricular rate early after the start of use without markedly deteriorating haemodynamics. After the cardiac status is stabilized by rapid control of HR, subsequent basic HF pharmacotherapy and rhythm control therapies will be effective for improving outcomes. Because of the pharmacokinetic properties of landiolol, if the patient suffers an adverse reaction such as hypotension or bradycardia, such effects can be quickly reversed by tapering the dose or discontinuing use altogether. Based on several clinical studies, this review discusses the efficacy, safety and role of intravenous landiolol in acute HR control in patients with atrial tachyarrhythmias and ADHF.

Introduction

Atrial tachyarrhythmias, including atrial fibrillation (AF), atrial flutter (AFL) and atrial tachycardia (AT), occur frequently in patients with worsening heart failure (HF).1–4 The development of atrial tachyarrhythmias in acute decompensated HF (ADHF) causes an uncontrolled heart rate (HR) with a shortened filling time and tachycardia-induced cardiomyopathy, reduces cardiac output and further exacerbates haemodynamics, further exacerbating HF and causing a decompensated HF state to persist.5–7

For emergency treatment of atrial tachyarrhythmias with a high ventricular rate, it is important to restore sinus rhythm, control the ventricular rate, and improve the haemodynamics. Restoring sinus rhythm is a key to restoring normal atrioventricular excitatory processes, regularizing and lowering HR and normalizing ventricular pumping function to improve left ventricular (LV) contractility. Therefore, the conversion and prevention of atrial tachyarrhythmias is required in the management of HF. Prompt rhythm control, for example, by electrical cardioversion, is required for persistent atrial tachyarrhythmias in the context of critical illness, but a high recurrence rate of atrial tachyarrhythmias is often observed among patients in whom initial cardioversion is successful.8 If acute rhythm control fails to restore sinus rhythm, the management of these patients remains challenging. Prompt and reliable HR control for atrial tachyarrhythmias has a role in improving haemodynamics in the context of ADHF.

Acute rate control

In patients with ADHF, atrial tachyarrhythmias are caused by an increased sympathetic drive. Therefore, beta blockers are useful for ventricular rate reduction.
and are preferred over digoxin due to their effectiveness under the condition of high sympathetic tone. The use of beta blockers clearly requires an incrementally calibrated dosage to achieve an HR that balances the need for rate control with other haemodynamic parameters. The non-dihydropyridine calcium channel blockers verapamil and diltiazem are also useful for ADHF patients with preserved LV systolic function. However, beta blockers and non-dihydropyridine calcium channel blockers often show a negative inotropic effect and a blood pressure-lowering effect and, especially when administered intravenously, are of limited use in ADHF patients with reduced LV systolic function and/or low blood pressure. Meanwhile, digoxin takes time to distribute and is often unsuccessful in an acute context. Current European Society of Cardiology (ESC) guidelines recommend the use of intravenous digoxin or amiodarone exclusively in an acute setting in patients with HF and reduced LV systolic function.

Landiolol as an ultra-short-acting intravenous beta-1 blocker

In the context of acute care, an intravenous beta blocker that lowers the ventricular rate by suppressing sympathetic activity but without markedly reduced blood pressure and is pharmacokinetically easy to turn on and off (start and stop) is desired.

Landiolol is a short-acting intravenous beta-1 blocker developed in Japan. Landiolol shows very high cardiac beta-1 selectivity (beta-1/beta-2 ≈ 250) and is higher than esmolol. Furthermore, studies using rabbits have reported that landiolol caused a less negative inotropic effect and less of a decrease in blood pressure than esmolol. Regarding pharmacokinetic properties, landiolol is rapidly metabolized in plasma by pseudocholinesterase and has a very short elimination half-life of approximately 4 min. The protein binding rate is 1.5-7.0% (in vitro), and the volume of distribution is 0.24 L/kg.

In Japan, landiolol was approved in July 2002 as urgent treatment for AF, AFL and sinus tachycardia during surgery; in 2006, it was also approved for postoperative tachyarrhythmias. Furthermore, in November 2013, the indications of AF and AFL in patients with impaired LV function were added.

Acute rate control in atrial fibrillation/flutter: landiolol vs. digoxin

The J-Land study was conducted to compare the acute effect of intravenous landiolol vs. intravenous digoxin for reducing ventricular rates in patients with AF/flutter and impaired LV function. This prospective randomized trial included 200 patients with ventricular rate ≥120 beats/min, New York Heart Association (NYHA) class III or IV and LV ejection fraction (LVEF) 25-50% who were randomized to receive either landiolol (n = 93) or digoxin (n = 107). Continuous intravenous administration of landiolol was started at a dose of 1.0 μg/kg/min and titrated up to 10 μg/kg/min according to the patient’s condition; administration lasted for ≥2 h and up to 72 h. Digoxin was administered intravenously at an initial dose of 0.25 mg (if treated with oral digoxin, 0.125 mg); after 2 h but no more than 72 h, more intravenous digoxin could be added according to the patient’s condition. The primary endpoint was the percentage of patients with both an HR <110 beats/min and at least a 20% decrease from baseline at 2 h after administration. The mean dose of landiolol at 2 h was 6.7 ± 3.2 μg/kg/min. The primary endpoint was achieved in 48.0% of patients treated with landiolol and in 13.9% of patients treated with digoxin (P < 0.001) (Table 1).

Regarding safety, there was no significant difference in adverse events between the landiolol and digoxin groups (32.3% vs. 32.7%, respectively). The most common adverse events were hypotension [7 (7.5%) of 93 patients in the landiolol group vs. 4 (3.7%) of 107 patients in the digoxin group] and nausea/vomiting [7 (7.5%) vs. 1 (0.9%)]. Other common adverse events (>3%) were increased serum creatinine and urea levels, defined as an increase in values from normal to abnormal, and constipation. During the trial, three patients discontinued landiolol due to adverse events, but none discontinued digoxin. Serious adverse events were observed in two patients in the landiolol group (congestive HF and stroke) and in three patients in the digoxin group (sinus arrest, diabetes insipidus and pneumonia).

This study showed that continuous intravenous landiolol, when used as an HR regulator for atrial tachyarrhythmias, can provide a more rapid HR reduction than intravenous digoxin without excessively lowering blood pressure. This effect was not affected by renal function and has been shown to be very useful in patients with AF and AF with impaired renal function.

Effect of landiolol on rapid atrial tachyarrhythmias in a clinical setting

Several clinical data on the efficacy and safety of intravenous landiolol on rapid tachyarrhythmias with HF have been reported (Table 1). These studies have focused on reductions in HR and blood pressure and adverse events, including hypotension and exacerbated HF. Although the optimal resting ventricular rate in patients with AF and HF is not certain, the ESC guidelines recommend 60-100 b.p.m. for patients with HF. In most Japanese studies, responders to landiolol have been defined as having HR decrease ≥ 20% or HR < 110 b.p.m. according to the criteria of the J-Land study.

The effect of landiolol depends on the dose. Administration usually starts at a dose of 1.0 μg/kg/min, and the maintenance dose ranges from 1.0 to 10.0 μg/kg/min. The average dose is reported to be 3.0-5.0 μg/kg/min, and an efficacy of approximately 70% or more as the response reaches the above criteria has been obtained. Of course, the goal of acute rate control is to stabilize haemodynamics. Interestingly, landiolol does not worsen haemodynamics even when used in
| Patient characteristics | Study design | Arm | Main results |
|--------------------------|--------------|-----|--------------|
| **Nagai et al.**<sup>15</sup> | Prospective, multicentre, randomized controlled trial | Continuous intravenous landiolol (n = 93), intravenous digoxin (n = 107) | HR decrease ≥20% or HR < 110 b.p.m. at 2 h: landiolol (average dose of 6.7 ± 3.2 μg/kg/min) 48.0%, digoxin (0.25 mg) 13.9%. Hypotension: landiolol 7 patients, digoxin 4 patients. |
| **Kobayashi et al.**<sup>16</sup> | Prospective, single-centre, non-comparative study | Continuous intravenous landiolol | At an average dose of 1.5 ± 0.4 μg/kg/min, the change in HR was −22.4% b.p.m. at 2 h; the HR decrease was greater in patients with LVEF < 50% than in patients with LVEF ≥50%. No hypotension (<60 mmHg). |
| **Adachi et al.**<sup>17</sup> | Continuous intravenous landiolol | Continuous intravenous landiolol | At an average dose of 10.8 ± 9.4 μg/kg/min, HR decreased from 133 ± 27 to 82 ± 15 b.p.m. (P < 0.01), and SBP decreased from 105 ± 21 to 101 ± 19 mmHg (P = ns). HR decrease ≥20% in all patients within 1 h. Hypotension: 3 patients. |
| **Wada et al.**<sup>18</sup> | Retrospective, two-centre, non-comparative study | Continuous intravenous landiolol | HR decrease ≥20% or HR < 110 b.p.m. within 3 h (responder): 29 patients (74%). The HR of responders (average dose of 4.9 ± 3.0 μg/kg/min) decreased from 152 ± 19 to 96 ± 17 b.p.m.; the HR of non-responders (average dose of 5.5 ± 4.2 μg/kg/min) decreased from 152 ± 10 to 137 ± 22 b.p.m. Hypotension (<80 mmHg): 3 patients. |
| **Kiuchi et al.**<sup>19</sup> | Continuous intravenous landiolol (n = 15), continuous intravenous diltiazem (n = 44) | Continuous intravenous landiolol | HR decrease ≥20% or HR < 110 b.p.m. at 3 h: landiolol (average dose of 5.57 ± 4.78 μg/kg/min), 8 patients (53%); diltiazem (average dose of 2.65 ± 1.26 μg/kg/min), 14 patients (32%); P = 0.009. Latency to switch to oral beta-blockers was shorter in the landiolol groups than in the diltiazem group (median: 2 vs. 4 days, P = 0.002). BP decrease: landiolol, mean SBP from 116 to 112 mmHg, P = ns, mean DBP from 70 to 64 mmHg, P = ns; diltiazem, mean SBP from 131.1 ± 23.7 to 121.1 ± 20.3 mmHg, p < 0.001, DBP from 81.4 ± 19.0 mmHg to 69.9 ± 13.3 mmHg, P < 0.001. |
| **Matsui et al.**<sup>20</sup> | Continuous intravenous landiolol | Continuous intravenous landiolol | At a median dose of 3.0 (range 1.0–12.0) μg/kg/min, HR decreased from 141 ± 17 to 99 ± 20 b.p.m. at 6 h |

*Continued*
patients with cardiac dysfunction. Kiuchi et al. retro-
spectively evaluated that intravenous diltiazem reached
the target HR less frequently than landiolol was associated
with showed lower blood pressure. The benefit of
intravenous landiolol is that it lowers the ventricular
rate early after the start of use without markedly deterior-
ating haemodynamics. Because of the pharmacokinetic
properties of landiolol, any adverse effects can be quickly

| Table 1 Continued |
| Patient characteristics | Study design | Arm | Main results |
|------------------------|-------------|-----|-------------|
| LVEF < 50% (n = 12), LVEF ≥ 50% (n = 11), Ischaemic aetiology 22%, NYHA FC III/ IV 60%, mean LVEF 41 ± 13%. | | | (P < 0.001), with no marked hypotension. 70% of discharged patients had SR, and these patients showed a lower frequency of rehospitalization due to worsening HF than patients without SR (5/41 vs. 7/18, P = 0.019). |
| Iwahashi et al. | 101 patients with AF, HR ≥ 120 b.p.m., NYHA FC IV, LVEF < 40% (median age 73 years, proportion of males 62%), Ischaemic aetiology 20%. | Prospective, single-centre, non-comparative study | Continuous intravenous landiolol | At an average dose of 3.8 ± 2.3 μg/kg/min, an HR decrease ≥ 20% or an HR < 110 b.p.m. within 24 h occurred in 95 (94%) patients. Among 37 patients who received RHC monitoring, HR decreased from 143 ± 17 to 97 ± 19 b.p.m. (P < 0.0001), and pulmonary capillary wedge pressure decreased from 23.6 ± 7.8 to 17.3 ± 6.3 (P = 0.0008). No bradycardia (< 50 b.p.m.) nor hypotension (SBP < 80 mmHg). |
| Oka et al. | 77 patients with AF/AFL/AT, HR ≥ 120 b.p.m., NYHA FC III/ IV, LVEF < 50% (mean age 72 ± 13 years, proportion of males 70%). Ischaemic aetiology 21%. | Retrospective, single-centre, comparative study | Continuous intravenous landiolol: AF group (n = 65) vs. AFL/AT group (n = 12) | HR decrease ≥ 20% or HR < 110 b.p.m. at 2 h: AF 72.3% vs. AFL/AT 16.7%, P = 0.0004. Maximum dose: AF 3.6 ± 2.4 μg/kg/min, AFL/AT 8.5 ± 2.4 μg/kg/min, P < 0.001. Alternative treatments such as intravenous amiodarone and electrical cardioversion were required in 83% of the AFL/AT patients. |
| Yamashita et al. | 1,121 patients with AF/AFL, cardiac dysfunction (mean age 73 ± 14 years, proportion of males 57%). NYHA FC III/IV 76.6%, median LVEF 40% (range 7-85%). | Prospective, multicentre, non-comparative study (post-marketing survey) | Continuous intravenous landiolol | HR decrease ≥ 20%: 77.5%. Adverse drug reactions: hypotension (30 events), aggravation of cardiac failure (11 events) and bradycardia (7 events). |
| Shinohara et al. | 53 patients with AF, HR ≥ 120 b.p.m., NYHA FC III/IV, LVEF ≤ 25% (mean age 67 ± 16 years, proportion of males 66%). Ischaemic aetiology 21%. | Retrospective, single-centre, comparative study | Continuous intravenous landiolol (n = 34), intravenous digoxin (n = 19) | HR decrease ≥ 20% or HR < 110 b.p.m. at 24 h (responders): landiolol (5.2 ± 2.7 μg/kg/min) 71.0% vs. digoxin (0.25 mg) 41.2%, P = 0.048. SBP was significantly decreased in the landiolol group but not in the digoxin group. Hypotension (SBP < 80 mmHg): 2 patients (landiolol). |

ADHF, acute decompensated heart failure; AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia; HF, heart failure; HR, heart rate; LVEF, left ventricular ejection fraction; NYHA FC, New York Heart Association functional class; SBP, systolic blood pressure.
restored by tapering the dose or discontinuing administration altogether. These features make the drug appropriate and easy to use in acute settings.

In patients with ADHF or severe HF who are unstable hemodynamic state, landiolol is limited to use in the intensive care unit. On the other hand, in patients with mild to moderate HF who are stable hemodynamic state, it can also be used in an ordinary ward. During intravenous landiolol therapy, electrocardiographic telemetry monitoring and frequent blood pressure measurement (especially after initiation until maintenance dose) are required to assess efficacy and safety.

Dosage of landiolol

In Japan, where landiolol is most commonly used in practice, maintenance dosages of for continuous intravenous infusion of landiolol range from 1.0 to 10.0 μg/kg/min (Table 2). However, landiolol, a beta-1 blocker, does not always achieve a sufficient effect in ADHF, where sympathetic nerve activity is enhanced. Adachi et al. reported that when a high dose (up to a maximum of 20 μg/kg/min) was used with a target of 20% reduction in HR, all patients were able to reach the target HR. Three patients developed transient hypotension, and landiolol administration was discontinued, but no serious adverse events occurred.

A Phase II trial in Austria, excluding HF patients of NYHA functional class III/IV, evaluated the efficacy and safety of higher dosages for rapid AF—continuous infusion at 40 μg/kg/min or a bolus dose of 100 μg/kg administered over 1 min followed by continuous infusion at 40 μg/kg/min and continuous infusion up to a maximum of 80 μg/kg/min—(maximum continuous infusion time of up to 210 min) and reported that only 3 of 20 patients developed transient hypotension; no serious adverse events occurred. This study used similar doses as those used in the pharmacokinetic study in Japanese patients with supraventricular/ventricular arrhythmias (20, 40 and 80 μg/kg/min; infusion time of 5 and 15 min). Additional studies conducted in different settings in Caucasian patients with supraventricular tachyarrhythmias in critical care patients and in HF patients showed similar dose-response with majority of patients using landiolol dose below 10 μg/kg/min (Table 3). Racial/ethnic differences in responsiveness to beta blockers have been noted and genetic subtype of beta-1 receptor can lead to different HR response. Although there are no racial/ethnic differences in the pharmacokinetic parameters of landiolol, these preliminary results in Caucasians appear to confirm no difference in its pharmacodynamics. However, further studies are needed to identify the appropriate dose for acute rate control in larger cohorts.

Haemodynamics

The HR-lowering effect of landiolol persisted throughout intravenous infusion. In general, however, there was no clinically significant excessive decrease in blood pressure during intravenous landiolol therapy (Table 2). Iwahashi et al. reported that among 37 patients with AF and ADHF (NYHA functional class IV, LVEF < 40%) who underwent right heart catheterization monitoring, HR decreased from 143 ± 17 to 97 ± 19 b.p.m. (P < 0.0001), main pulmonary artery pressure decreased from 31.1 ± 8.2 to 25.0 ± 5.3 mmHg (P = 0.004), pulmonary capillary wedge pressure decreased from 23.6 ± 7.8 to 17.3 ± 6.3 mmHg (P = 0.0008) and stroke volume increased from 25.5 ± 13.6 to 32.4 ± 11.6 mL/beat (P = 0.02) during continuous infusion of landiolol. However, cardiac output, right atrial pressure and systemic vascular resistance did not change during landiolol infusion. These findings suggested that landiolol improves stroke volume by improving LV filling due to lowering HR without a drop in cardiac output, since landiolol exhibits a slight negative inotropic effect. These effects are advantageous for patients with low LVEF. Matsui et al. reported that in four patients with severe systolic dysfunction (LVEF ≤ 30%), intravenous landiolol did not decrease blood pressure or worsen the haemodynamic state, and as a result, the LVEF values of these patients were improved after landiolol therapy.

Atrial fibrillation and other atrial tachyarrhythmias (atrial flutter/atrial tachycardia)

AFL and AT are also relatively common atrial tachyarrhythmias, which are characterized by rapid, regular atrial rhythm with a regular ventricular rate. In patients with AFL/tachycardia, pharmacological rate control often has difficulty achieving adequate HR reduction. Oka et al. reported that the magnitude of HR reduction was diminished in patients with AF compared with patients with AFL/AT despite a higher dose of landiolol (% change in HR from baseline to 12 and 24 h was only −10.2 ± 12.7% and −16.1 ± 19.4% in patients with AFL/AT, −28.3 ± 13.2% and −31.3 ± 11.3% in patients with AF (P = 0.02), respectively (Table 2). The prevalence of reaching the target HR (an HR decrease of ≥20% or HR < 110 b.p.m.) with landiolol was higher in patients with AF than in patients with AFL/AT (72.3% vs. 16.7%, P < 0.001). For AFL/AT, alternative therapies, including intravenous amiodarone or digoxin, and prompt cardioversion should be considered if intravenous landiolol fails to achieve sufficient rate control.

LVEF

The ESC guidelines state that the drug choice for acute HR control in AF depends on the LVEF; beta blockers are the first-line treatment for patients with an LVEF of ≥40% or < 40%. Kobayashi et al. reported that patients with an LVEF of ≥50% experienced a much larger decrease in HR than patients with an LVEF < 50% 1-2 h after the start of landiolol treatment, although there was no difference at later time points. Ozaki et al. reported that AF patients with an LVEF ≥40% showed a much larger
Table 2  Dose and hemodynamic profiles of landiolol studies in Japanese patients with atrial fibrillation and heart failure

| Subjects (by condition) | Number | NYHA functional class | LVEF (%) | Initial dose (μg/kg/min) | Maintenance dose (μg/kg/min) | HR (b.p.m.) | SBP |
|-------------------------|--------|-----------------------|----------|--------------------------|-----------------------------|-------------|-----|
| Kobayashi et al. 16     | 23     | ≥ 3                   | 45.1 ± 13.5 | 1.0                      | 1.5 ± 0.4                   | 139.0 ± 14.8 | −22.4% |
| Adachi et al. 17        | 52     | ≥ 3                   | 32.3 ± 11.9 | 1.0                      | 10.8 ± 9.4                  | 133.3 ± 27.3 | 15.3 |
| Wada et al. 18          | 39     | ≥ 3 (87%)             | 34 ± 16   | 1.0                      | 4.8 ± 3.3                   | 152 ± 19     | 88 ± 29 |
| Kiuchi et al. 19        | 15     | 3                     | 42        | 0.5-1.0                  | 5.57 ± 4.78                 | 132 → 98 (at 2 h) |
| Matsui et al. 20        | 67     | ≥ 2, ≥ 3 (60%)        | 41 ± 13   | 1.0                      | Median 3.0 (range 1.0-12.0) | 141 ± 17 → 99 ± 20 (at 6 h) |
| Iwahashi et al. 21      | 101    | 4                     | 22 (18-32) | 1.0                      | 3.8 ± 2.3                   | (n = 37) 143 ± 17 → 97 ± 19 |
| Oka et al. 22           | 77     | ≥ 3                   | 33.1 ± 13.7 | 1.0                      | AFL/AT: 8.5 ± 3.0           | AFL/AT: 149.2 ± 10.8 → 139.2 ± 16.8 (at 2 h) |
| Shinohara et al. 24     | 53     | ≥ 3                   | 23.6 ± 4.0 | 0.5-1.0                  | 5.2 ± 2.7                   | 142.9 ± 15.8 → 97.5 ± 17.2 (at 24 h) |

ADHF, acute decompensated heart failure; AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia; HR, heart rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure.
Table 3  Patient characteristics, study design and main results of landiolol studies in Caucasian patients with atrial tachyarrhythmias and/or HF

| Study design | Landiolol dosing | Main results |
|--------------|------------------|--------------|
| Median HR decrease by 20.5 b.p.m., corresponding to a reduction of −17.2%, at 16 min. Overall reduction of AF/AFL symptoms at 16 min was 72%. Hypotension: 20 patients. No serious adverse events. | Continuous intravenous landiolol (n = 10) 100 µg/kg bolus administered over 1 min + 40 µg/kg/min up to a maximum of 80 µg/kg/min, Infusion landiolol (n = 10) 40 µg/kg/min up to maximum of 80 µg/kg/min. | Prospective, single-centre, open label trial |
| Bolus + Infusion landiolol (n = 10) 100 µg/kg bolus administered over 1 min + 40 µg/kg/min up to a maximum of 80 µg/kg/min. | AF Patients showed HR decrease of 22 ± 7%, while patient with sinus tachycardia showed less HR reduction (−9%). After 2 hrs infusion hemodynamic stability (mean SBP 97 ± 12 mmHg, mean DBP 59 ± 6 mmHg, mean MAP 71 ± 10 mmHg). One septic patient with high dose catecholamine did not tolerate landiolol. | Consecutive series of critically ill patients with tachycardia and hypotension |
| Continuous intravenous landiolol (n = 10) | HR reduction was 23% [115 (108-117) vs. 150 (138-160)] b.p.m. without any negative impact on global hemodynamic or tissue perfusion parameters during landiolol infusion, Norepinephrine need decreased in 9/11 patients (81%), and mean norepinephrine dose significantly decreased [0.7 (0.2-1) vs. 1.0 (0.4-1.5) µg/kg/min]. | Consecutive series of patients critically ill patients with tachycardia and hypotension |
| Landiolol infusion was started at 0.2 µg/kg/min and dosage reached 3.9 (1.6-7.0) µg/kg/min at 24 h. | Concomitant administration of landiolol (10-20 µg/kg/min) and levosimendan (0.1 µg/kg/min) is well tolerated provides improved cardiac function improvement and stroke volume normalization, along with norepinephrine dose reduction. | Continuous intravenous landiolol (n = 15) |
| Continuous intravenous esmolol (n = 20) (100 µg/kg/min) | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Continuous intravenous landiolol (n = 10) |
| Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Continuous intravenous landiolol (n = 10) | Continuous intravenous landiolol (n = 10) |
| Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Continuous intravenous esmolol (n = 20) (100 µg/kg/min) | Continuous intravenous esmolol (n = 20) (100 µg/kg/min) |
| Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. |
| Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. |
| | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. |
| | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. |
| | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. |
| | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. | Landiolol produces a faster and deeper HR decrease compared with esmolol (−40 ± 20 vs. −30 ± 16 b.p.m.) without any hemodynamics deterioration as opposed to esmolol which was associated with a significant MAP reduction. |

---

**Patient characteristics (*group treated with landiolol)*

| Study design | Landiolol dosing | Main results |
|--------------|------------------|--------------|
| | | |
Table 3 Continued

| Patient characteristics (*group treated with landiolol) | Study design | Landiolol dosing | Main results |
|---------------------------------------------------------|--------------|-----------------|--------------|
| Ditali et al.                                            | 2 patients with AF and ADHF. Patient A (age 44 years, male): HR 140 b.p.m., NYHA FC III, LVEF 15% Patient B (age 20 years, female): HR 120 b.p.m., NYHA FC II, LVEF 25%. | Series of 5 critically ill patients treated with a combination of inotropes and a low dose of landiolol | Continuous intravenous landiolol (6 and 9 μg/kg/min). | Patient A (9 μg/kg/min): HR decreased from 140 to 90 b.p.m. and SBP decreased from 130 to 120 mmHg. LVEF increased (LVEF 35%) and NT-proBNP decreased from 1,553 to 1,284 pg/mL. Patient B (6 μg/kg/min): HR decreased from 120 to 66 b.p.m. and SBP increased from 88 to 100 mmHg. LVEF did not change (LVEF 25%), but NT-proBNP decreased from 13,130 to 7,008 pg/mL. |

ADHF, acute decompensated heart failure; AF, atrial fibrillation; AFL, atrial flutter; DBP, diastolic blood pressure; HF, heart failure; HR, heart rate; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; NT-proBNP, N-terminal probrain natriuretic peptide; NYHA FC, New York Heart Association functional class; SBP, systolic blood pressure; SOFA, Sequential Organ Failure Assessment; ST, sinus tachycardia.

Even in patients with severe LV systolic dysfunction (LVEF <30%), landiolol therapy could be continued without haemodynamic deterioration, and the LVEF values of these patients could improve after landiolol therapy. However, it may be important to characterize LV systolic function when administering continuous intravenous landiolol.

Outcomes

Landiolol reliably lowers the HR and improves haemodynamics in patients with atrial tachyarrhythmias and ADHF. Matsui et al. reported that 22% of the patients receiving landiolol exhibited spontaneous restoration of sinus rhythm, and when defibrillation was added, 42 (63%) of the 67 patients showed a restored sinus rhythm during hospitalization. Wada et al. also reported that 9 (31%) of 29 patients who responded to landiolol (HR decrease ≥20% or HR <110 b.p.m. within 3 h) exhibited spontaneous restoration of sinus rhythm, and when defibrillation was added, 21 (54%) of the 39 patients showed a restored sinus rhythm.

In HF, sympathetic nerve activity is enhanced, and the stimulation of beta-adrenergic receptors alters the activity of several ion channels and transporters, which leads to arrhythmogenesis. Landiolol may be effective in treating atrial tachyarrhythmias due to increased sympathetic drive in HF.

After landiolol therapy, further introduction or strengthening of basic pharmacotherapy for HF (such as the use of beta blockers and renin-angiotensin-aldosterone system inhibitors) and additional rhythm control strategies were provided to improve outcomes. Matsui et al. reported that 41 (69%) of the 59 patients who were alive at discharge were in sinus rhythm (Figure 1). Rehospitalization due to worsening HF occurred less frequently in patients who were discharged with sinus rhythm than in those discharged with atrial tachyarrhythmias (5/41 vs. 7/18, P = 0.019). Yamashita et al. also reported from a post-marketing survey that patients who were switched from landiolol to oral beta blockers had lower all-cause mortality and HF-specific mortality than those who were not switched [hazard ratio 0.39, 95% confidence interval (CI) 0.28–0.55; hazard ratio 0.40, 95% CI 0.23–0.70, respectively]. Kiuchi et al. reported that the latency to switch to oral beta blockers was shorter in patients receiving intravenous landiolol than in patients receiving intravenous diltiazem (median: 2 vs. 4 days, P = 0.002). Adachi et al. reported that 44 of 52 patients could switch from intravenous landiolol to oral beta blockers, 28 patients received additional non-pharmacological therapies such as catheter ablation, cardiac resynchronization therapy and valve surgery, and 49 discharged patients were in NYHA functional class I/II.
In patients with atrial tachyarrhythmias and ADHF, the restoration of sinus rhythm improves haemodynamics and cardiac function, and additional therapies for HF and the restoration and maintenance of sinus rhythm may prevent HF exacerbation and lead to a subsequent improvement in prognosis. In acute care settings, there is a high recurrence in patients in whom initial cardioversion is successful. It is difficult to restore and maintain sinus rhythm in patients with deteriorated haemodynamics. In this situation, intravenous landiolol may be useful as the first-line therapy for improving the haemodynamic status by lowering the HR. After the cardiac status is stabilized, subsequent rhythm control therapy, such as cardioversion and catheter ablation, will be effective, although sinus rhythm cannot be restored during landiolol treatment. It is necessary to stabilize haemodynamics by rapidly controlling the rate of atrial tachyarrhythmias in patients with ADHF. Landiolol may reliably lower the HR during atrial tachyarrhythmias in ADHF patients without degrading their haemodynamics.

Safety

There have been no serious adverse reactions to landiolol in previous reports (Table 1). However, as one might expect given the pharmacological properties of the drug, hypotension, excessive bradycardia and worsening HF have been reported, although they are not frequent. These adverse drug reactions do not seem to be dose dependent. Wada et al. reported that hypotension was observed as an adverse effect in approximately 10% of patients with atrial or ventricular tachyarrhythmias who received intravenous landiolol and that hypotension was associated with a reduced LVEF (<25%).

Due to the pharmacokinetic properties of landiolol, including a very short elimination half-life and restricted distribution, the drug is rapidly eliminated, and the patient’s condition reverts quickly if administration is discontinued. This may be the main reason adverse reactions to landiolol do not lead to serious adverse events in an acute-care setting.

Conclusion

In the context of acute care, intravenous landiolol reduced the HR without markedly decreasing blood pressure in patients with atrial tachyarrhythmias and ADHF. Hypotension, excessive bradycardia and worsening HF have been observed as adverse effects but are less frequent, and the patient’s condition recovers soon if administration is discontinued. Intravenous landiolol is recommended to acutely control HR in patients with atrial tachyarrhythmias and worsening HF, especially reduced LV systolic function (LVEF <40%) in acute setting. It can also be used to reduce HR in patients with haemodynamic instability. Stabilizing the cardiac status in the early period of ADHF by rapid HR control leads into subsequent HF pharmacotherapy and rhythm control therapies and will contribute to the improvement of outcomes.
Funding
This paper was published as part of a supplement financially supported by AOP Orphan Pharmaceuticals GmbH.

Conflict of interest: T. S. received research funding and lecture fees from ONO Pharmaceutical Co., Ltd.

Data availability
No new data were generated or analysed in support of this research.

References
1. Nieuwlaat R, Eurlings LW, Cleland JG, Cobbe SM, Vardas PE, Capucci A, López-Sendon JL, Meeder JG, Pinto YM, Crijns HJ. Atrial fibrillation and heart failure: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro heart survey on atrial fibrillation. J Am Coll Cardiol 2009; 53:1690–1698.
2. Li SJ, Sartipy U, Lund LH, Dahlström U, Adlés M, Petzold M, Fu M. Prognostic significance of resting heart rate and use of β-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: findings from the Swedish heart failure registry. Circ Heart Fail 2015; 8:871–879.
3. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham heart study. Circulation 1998; 98:946–952.
4. Fioretti MC, Fedele M, Cappato R, Fedele F, Lazzara R, Palatini P, Pozzato G, Zoppini G. Combined management of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003; 107: 2920–2925.
5. Crijns HJGM, Van Der Burg MP, Van Gelder JC, Van Veldhuisen DJ. Management of atrial fibrillation in the setting of heart failure. Eur Heart J 1997; 18:C45–C49.
6. Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: a vicious electrolytic cycle. Circulation 2004; 109:2839–2843.
7. Kotecha D, Piccini JP. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and heart failure among patients with atrial fibrillation. Eur Heart J 2015; 36:3250–3257.
8. May A, Ritzch N, Kwoitzer H, Dünser M, Schobersberger W, Ulmer H, Mutz N, Hasibeder W. Effectiveness of direct-current cardioversion for treatment of supraventricular tachyarrhythmias, in particular atrial fibrillation, in surgical intensive care patients. Crit Care Med 2003; 31:401–405.
9. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Borlini G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, Le Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, ESC Scientific Document Group 2020. ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42:373–498.
10. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel G, Cleland JGF, Coats AJS, Crepo-Leiro MG, Farmakis D, Gillard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJJ, McPee J, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Skibielka RA, ESC Scientific Document Group 2021. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42:373–498.
11. Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, Sakaki K, Hachiyi K, Ichikom Y, Kawamura M. Development of a highly cardioselective ultra-short-acting β-blocker. ONO 1101. Chem Pharm Bull 1992; 40:1462–1469.
12. Domanovits H, Wolzt M, Stix G. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting. Eur Heart J Suppl 2018; 20:A1–A3.
13. Plosker GL. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs 2013; 73:975–997.
14. Sasaki J, Ohara T, Saito J, Uchino K, Sakaki K, Hachiya K, Ichioka Y, Kawamura M, Doi M, Nao T, Wada Y, Matsuzaki M, Yano M. A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation. Cardiology 2014; 127:105–113.
15. Kobayashi S, Murakami W, Myoren T, Tateshi H, Okuda S, Doi M, Nao T, Wada Y, Matsuzaki M, Yano M. A low-dose β1-blocker effectively and safely slows the heart rate in patients with acute decompensated heart failure and rapid atrial fibrillation. Cardiology 2014; 127:105–113.
16. Kotecha D, Piccini JP. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and heart failure among patients with atrial fibrillation. Eur Heart J 2015; 36:3250–3257.
17. Iwahashi N, Takahashi H, Abe T, Okada K, Akiyama E, Matsuzyawa S, Konishi M, Maejima N, Hibi K, Kosuge M, Ebina T, Tamura K, Kimura K. Urgent control of rapid atrial fibrillation by landiolol in patients with acute decompensated heart failure with severely reduced ejection fraction. Circ Rep 2019; 1:422–430.
18. Oka E, Iwasaki YK, Maru E, Fujimoto Y, Ito-Hagiwara K, Hayashi T. Effectiveness of landiolol in atrial fibrillation patients with left ventricular dysfunction. J Clin Med Res 2017; 9:426–432.
19. Matsui Y, Suzuki A, Shiga T, Araki K, Hagiwara N. Effects of intravenous landiolol on heart rate and outcomes in patients with atrial tachyarrhythmias and acute decompensated heart failure: a single-center experience. Drugs Real World Outcomes 2019; 6:19–26.
20. Iwahashi N, Takahashi H, Abe T, Okada K, Akiyama E, Matsuzyawa S, Konishi M, Maejima N, Hibi K, Kosuge M, Ebina T, Tamura K, Kimura K. Urgent control of rapid atrial fibrillation by landiolol in patients with acute decompensated heart failure with severely reduced ejection fraction. Circ Rep 2019; 1:422–430.
21. Oka E, Iwasaki YK, Maru E, Fujimoto Y, Ito-Hagiwara K, Hayashi T, Yamamoto T, Yodogawa K, Hayashi M, Shimizu W. Differential effectiveness of landiolol between atrial fibrillation and atrial flutter/atrial tachycardia patients with left ventricular dysfunction. Circ J 2019; 83:793–800.
22. Yamashita T, Nakazawa Y, Mizutani H, Sumitani K. A prospective observational study on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CF landiolol survey. J Cardiovasc Med 2019; 74:418–425.
23. Shinohara H, Wada S, Yano K, Akitsu K, Kolke H, Kinoshita T, Suzuki T, Fujino T, Ikeda T. Comparison of landiolol and digoxin as an intravenous drug for controlling the heart rate in patients with atrial fibrillation and severely depressed left ventricular function. Int J Heart 2020; 61:944–950.
24. Kinugawa K, Nakai R, Inoue H, Arai K, Kobayashi K, Sakaki K, Hachiya K, Ichikom Y, Kawamura M. Development of a highly cardioselective ultra-short-acting β-blocker. ONO 1101. Chem Pharm Bull 1992; 40:1462–1469.
28. Weinmann K, Hartveg P, Buckert D, Pett A, Petscher K, Imhof A, Rottbauer W, Dahme T. First experience with the ultra-short acting intravenous cardioselective beta-blocker landiolol on the intensive care unit in Germany: a case series. Clin Res Cardiol 2018; 107(Suppl. 3).

29. Hariri G, Urbina T, Mazerand S, Bige N, Baudel JL, Att-Oufella H. Rate control in atrial fibrillation using Landiolol is safe in critically ill Covid-19 patients. Crit Care 2021; 25:33.

30. Dabrowski W, Siwicka-Gieroba D, Piasek E, Schlegel TT, Jarosynski A. Successful combination of landiolol and levosimendan in patients with decompenated heart failure. Int Heart J 2020; 61:384-389.

31. Anifanti M, Iona I, Tsikritsaki K, Chrysikos S, Kalogeromitros A, Koukoulitsios G. Landiolol vs esmolol on hemodynamic response during weaning of post-operative ICU patients with heart failure. Eur Respir J 2021; 58:A3320.

32. Ditali V, Garatti L, Morici N, Villanova L, Colombo C, Oliva F, Sacco A. Effect of landiolol in patients with tachyarhythmias and acute decompensated heart failure (ADHF): a case series. ESC Heart Fail 2022; 9:766-770.

33. Verschuren JJW, Trompet S, Wessels JAM, Guchelaar HJ, de Maat MPM, Simoons ML, Jukema JW. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J 2012; 33:165-175.

34. Muszkat M, Hoofen A, Orlanski-Meyer E, Makhouli H, Porat E, Davidson EM, Blotnick S, Caraco Y. The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β1(1) adrenergic receptor antagonist esmolol in healthy individuals. Pharmacogenet Genomics 2013; 23:25-28.

35. Krumpf G, Leč J, Trebs M, Kadlecová P, Hodlsch J, Maurer G, Husch B. Pharmacodynamic and -kinetic behavior of low-, intermediate-, and high-dose Landiolol during long-term infusion in whites. J Cardiovasc Pharmacol 2017; 70:42-51.

36. Ozaki T, Yamada T, Morita T, Furukawa Y, Tamaki S, Iwasaki Y, Kawasaki K, Kikuchi A, Kondou T, Sato Y. Urgent control of rapid atrial fibrillation using landiolol in patients with acute decompensated heart failure with reduced or preserved left ventricular ejection fraction. Eur Heart J 2016; 37:1319.

37. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res 2014; 114:1500-1515.

38. Yamashita T, Nakasu Y, Mizutani H, Sumitani K. Mid-term prognosis after landiolol treatment in atrial fibrillation/atrial flutter patients with chronic heart failure- a prospective observational survey (AF-CHF landiolol survey). Circ Res Rep 2020; 3:34-43.